23:20 , Jul 26, 2019 |  BC Extra  |  Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
07:00 , Jun 16, 2014 |  BioCentury  |  Strategy

Nucleotide arms race

The acquisition of Idenix Pharmaceuticals Inc. will fill a hole in Merck & Co. Inc. 's HCV toolbox and give the pharma a chance to develop an interferon-free regimen that can treat all patients at...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Financial News

Synergy financial update

Synergy's ContraVir Pharmaceuticals Inc. subsidiary filed a Form 10 with the SEC to become a publicly reporting company listed on the OTC Bulletin Board. Synergy created the subsidiary in May to house shingles product FV-100...
23:35 , Aug 9, 2013 |  BC Extra  |  Financial News

ContraVir seeking public listing

The ContraVir Pharmaceuticals Inc. subsidiary of gastrointestinal company Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) filed a Form 10 with the SEC to become a publicly reporting company listed on the OTC Bulletin Board. Synergy created the subsidiary...
07:00 , Apr 29, 2013 |  BioCentury  |  Product Development

Plan B in HCV

Bristol-Myers Squibb Co. 's HCV ambitions did not die with Inhibitex Inc. 's INX-189. The pharma believes its next choice for all-oral regimen involving NS3 protease, NS5A protein and non-nucleoside NS5B inhibitors has the safety...
08:00 , Feb 25, 2013 |  BioCentury  |  Finance

Ready to go solo

Ready to go solo Investors hoping Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) would be taken out in the HCV gold rush might take last week's $126 million follow-on as a signal that the company now expects to...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Biota Pharmaceuticals management update

Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Rockville, Md.   Business: Infectious, Neurology, Cancer   Hired: Joseph Patti as EVP of corporate development and strategy, formerly SVP of R&D and CSO of Inhibitex Inc. , which Bristol-Myers Squibb...
07:00 , Sep 10, 2012 |  BioCentury  |  Product Development

Inhibitex's Tox

Bristol-Myers Squibb Co. may have looked past in vitro safety signals in a rush to add Inhibitex Inc. 's nucleoside NS5B polymerase inhibitor to its HCV portfolio. If the pharma was gambling that it could...